PCDHGC4: A Potential Drug Target and Biomarker for Proliferative diseases

Target Name: PCDHGC4

NCBI ID: G56098

PCDHGC4: A Potential Drug Target and Biomarker for Proliferative diseases

Proliferative diseases are a significant public health burden worldwide, affecting millions of individuals across various malignancies, including breast, ovarian, and skin cancers. The development of new therapeutic approaches for these diseases remains a major focus in the pharmaceutical industry. PCDHGC4, a gene encoding a protein known as protocadherin gamma subfamily C, 4 (PCDHGC4), has emerged as a promising candidate for drug targeting and biomarker in the context of proliferative diseases. In this article, we will provide an overview of PCDHGC4, its functions in cancer progression, potential drug targeting strategies, and its potential as a biomarker for diagnosing and monitoring these diseases.

PCDHGC4 gene and function

PCDHGC4 is a member of the protocadherin gene family, which is known for its role in cell-cell adhesion and tissue organization. The PCDHGC4 gene encodes a 21-kDa protein that belongs to the gamma subfamily of protocadherins (PCDHGC1-3). This protein is involved in various cellular processes, including cell adhesion, migration, and invasion, and has been implicated in the development and progression of several cancers.

PCDHGC4 is expressed in various tissues and organs, including breast, ovarian, skin, and bone marrow. It is highly expressed in breast tissue, where it is one of the most abundant genes in the breast epithelial tissue. In ovarian tissue, PCDHGC4 is expressed in the epithelial and stromal cells, whereas in skin and bone marrow, it is mainly expressed in the epithelial cells.

PCDHGC4 is involved in several essential functions in cancer progression, including cell adhesion, migration, and invasion. It plays a critical role in the regulation of cell surface properties, such as cell adhesion, which is a critical step in the development of cancer. PCDHGC4 is known to be involved in cell-cell adhesion, and its expression has been shown to be associated with the development of several cancers, including breast, ovarian, and skin cancers.

PCDHGC4 as a drug target

PCDHGC4 has been identified as a potential drug target for cancer treatment due to its involvement in cell adhesion and migration. Several studies have shown that inhibiting PCDHGC4 can lead to the inhibition of cancer cell growth and migration.

One of the most promising strategies for targeting PCDHGC4 is the use of small molecules, such as inhibitors, that can disrupt its functions in cell adhesion and migration. Several studies have shown that inhibitors of PCDHGC4 have the potential to be effective in treating various cancers, including breast, ovarian, and skin cancers.

PCDHGC4 as a biomarker

PCDHGC4 has also been identified as a potential biomarker for the diagnosis and monitoring of cancer. The expression of PCDHGC4 has been shown to be associated with the development and progression of several cancers, including breast, ovarian, and skin cancers. Therefore, PCDHGC4 can be used as a biomarker for the diagnosis and monitoring of cancer.

Several studies have shown that the expression of PCDHGC4 can be used as a predictive factor for the outcomes of cancer patients, including the likelihood of recurrence and the response to chemotherapy. For instance, one study showed that high expression of PCDHGC4 was associated with poor prognosis in patients with breast cancer.

Conclusion

In conclusion, PCDHGC4 is a promising candidate for drug targeting and biomarker in the context of proliferative diseases. Its functions in cell adhesion, migration, and invasion make it an attractive target for cancer treatment. Several studies have shown that inhibiting PCDHGC4 can lead to the inhibition of cancer cell growth and migration. Additionally, PCDHGC4 has

Protein Name: Protocadherin Gamma Subfamily C, 4

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

More Common Targets